AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.41
−4.51%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.38
- Revenue estimate
- $59.4K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.39
- EPS estimate
- -$0.36
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +0.1%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $46
- PT range
- $26 – $57
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.36 | -$0.39 | Miss -8.06% | — |
| May 7, 2026 | -$0.34 | -$0.37 | Miss -8.82% | — |
| Mar 3, 2026 | -$0.31 | -$0.30 | Beat 3.23% | — |
| Nov 6, 2025 | -$0.43 | -$0.37 | Beat 13.95% | — |
| Aug 7, 2025 | -$0.44 | -$0.46 | Miss -4.55% | — |
| May 8, 2025 | -$0.45 | -$0.42 | Beat 6.67% | — |
| Mar 4, 2025 | -$0.49 | -$0.55 | Miss -12.24% | $665.0K |
| Nov 7, 2024 | -$0.47 | -$0.53 | Miss -12.77% | $416.0K |
| Aug 8, 2024 | -$0.38 | -$0.73 | Miss -92.11% | $1.0M |
| May 9, 2024 | $0.24 | -$0.46 | Miss -291.67% | $88.6M |
| Feb 22, 2024 | $0.23 | $0.07 | Miss -69.57% | $108.4M |
| Nov 9, 2023 | $0.44 | $0.30 | Miss -31.82% | $102.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026